The study compared patients who were taking GLP-1 medications with an equal number of matched patients who were not using the drugs
brain-derived GLP-1 for controlling feeding and body weight
Dietary and lifestyle modifications: Patients benefit from specific guidance regarding eating patterns and food choices: Smaller, more frequent meals Consuming 5-6 small meals rather than 3 large meals reduces gastric distension Slower eating pace Taking 20-30 minutes per meal and chewing thoroughly Avoiding high-fat foods Fatty meals delay gastric emptying further and may exacerbate symptoms Limiting very high-fiber foods During symptomatic periods, as these can worsen bloating Limiting carbonated beverages Reducing bloating and distension Adequate hydration Maintaining fluid intake between meals rather than with meals Remaining upright after eating Avoiding recumbent positions for 2-3 hours post-meal Symptomatic management: When lifestyle modifications prove insufficient, pharmacological interventions may provide relief
Its actions on GLP-1 and GIP receptors promote delayed gastric emptying and appetite control, offering a comprehensive approach to obesity research distinct from older GLP-1 agonists.
The food moves in your intestine slowly and stays in the stomach for a longer time, which reduces hunger cravings
But as trials progressed, it was obvious that patients were losing weight relatively quickly
